Hemodynamic effects of 5-aminolevulinic acid in humans

Journal of Photochemistry and Photobiology B: Biology

Volumn 43, Issue 1, 1998, Pages 61-65

  Herman, Mark A ^a   Webber, John ^a   Fromm, David ^a   Kessel, David ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Aminolevulinic acid; Hemodynamic effects; Photodynamic therapy; Protoporphyrin IX

Indexed keywords

AMINOLEVULINIC ACID; PHOTOSENSITIZING AGENT; PROTOPORPHYRIN;

ABDOMINAL SURGERY; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART INDEX; HEART OUTPUT; HUMAN; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; ORAL DRUG ADMINISTRATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PULSE RATE; SWAN GANZ CATHETER; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE;

AMINOLEVULINIC ACID; BLOOD PRESSURE; CAPILLARIES; CARDIAC OUTPUT; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; PHOTOCHEMOTHERAPY; PROTOPORPHYRINS; PULMONARY ARTERY; PULMONARY WEDGE PRESSURE; PULSE; VASCULAR RESISTANCE;

CYGNUS;

EID: 0032053065     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1011-1344(98)00086-4     Document Type: Article

References (25)

1. [1] J. Regula, A.J. MacRobert, A. Gorchein, G.A. Buonaccorsi, T.M. Thorpe, G.M. Spencer, A.R.W. Hatfield, S.G. Bown, Photosensitization and photodynamic therapy of oesophageal, duodenal, and colorectal tumors using 5 aminolevulinic acid induced protoporphyrin IX - a pilot study, Gut 36 (1995) 67-75.
2. [2] Q. Peng, K. Berg, J. Moan, M. Kongshaug, J.M. Nesland, 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem. Photobiol. 65 (2) (1997) 235-251.
3. [3] J. Webber, D. Kessel, D. Fromm, Side effects and photosensitization of human tissues after aminolevulinic acid, J. Surg. Res. 68 (1997) 31-37.
4. 15N, Biochem. J. 64 (1956) 80-90.
5. [5] J.C. Kennedy, R.H. Pottier, Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy, J. Photochem. Photobiol. B: Biol. 14 (1992) 275-292.
6. [6] W.E. Grant, C. Hopper, A.J. MacRobert, P.M. Speight, S.G. Bown, Photodynamic therapy of oral cancer: photosensitization with systemic aminolevulinic acid, Lancet 342 (1993) 147-148.
7. [7] Q. Peng, J. Moan, T. Warloe, J.M. Nesland, C. Rimington, Distribution and photosensitizing efficiency of porphyrins induced by application of endogenous 5-aminolevulinic acid in mice bearing mammary carcinoma, Int. J. Cancer 52 (1992) 433-443.
8. [8] L. Gossner, R. Sroka, E.G. Hahn, C. Eli, Photodynamic therapy: successful destruction of gastrointestinal cancer alter oral administration of aminolevulinic acid. Gastrointest. Endocrinol. 41 (1995) 55-58.
9. [9] Q. Peng, T. Warloe, J. Moan, H. Heyerdahl, H.B. Steen, J.M. Nesland, K.E. Giercksky, Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma, Photochem. Photobiol. 62 (1995) 906-913.
10. [10] J.A. Stein, D.P. Tschudy, Acute intermittent porphyria: a clinical and biochemical study of 46 patients, Medicine 49 (1) (1970) 1-16.
11. [11] G.H. Elder, R.J. Hift, P.N. Meissner, The acute porphyrias, Lancet 349 (1997) 1613-1617.
12. [12] N.F. Jensen, D.S. Fiddler, V. Striepe, Anesthetic considerations in porphyrias, Anesth. Analg. 80 (1995) 591-599.
13. [13] D.P. Tschudy, M. Valsamis, C.R. Magnussen, Acute intermittent porphyria: clinical and selected research aspects, Ann. Int. Med. 83 (6) (1975) 851-864.
14. [14] A.D. Beattie, M.R. Moore, A. Goldberg, R.L. Ward, Acute intermittent porphyria: response of tachycardia and hypertension to propanolol, Br. Med. J. 3 (1973) 257-260.
15. [15] H.L. Bonkowsky, D.P. Tschudy, Hazard of propanolol in the treatment of acute porphyria, Br. Med. J. 4 (1974) 47-48.
16. [16] N. Schoenfeld, O. Epstein, A. Atsmon, The effect of beta-adrenergic blocking agents on experimental porphyria induced by 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) in vivo and in vitro, Biochemica et Biophysica Acta 444 (1976) 286-293.
17. [17] D. Douer, A. Weinberger, J. Pinkhas, A. Atsmon, Treatment of acute intermittent porphyria with large doses of propanolol. JAMA 240 (1978) 766-768.
18. [18] M.F. Beal, N.O. Atuk, T.C. Westfall, S.M. Turner, Catecholamine uptake, accumulation, and release in acute porphyria, J. Clin. Investig. 60 (1977) 1141-1148.
19. [19] P. Mustajoki, K. Timonen, A. Gorchein, A.M. Seppäläinen, E. Matikainen, R. Tenhunen, Sustained high plasma 5-aminolevulinic acid concentration in a volunteer: no porphyric symptoms, Eur. J. Clin. Invest. 22 (1992) 407-411.
20. [20] A. Verma, J.S. Nye, S.H. Snyder, Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor, Proc. Natl. Acad. Sci. USA 84 (1987) 2256-2260.
21. [21] S.H. Snyder, A. Verma, R.R. Trifiletti, The peripheral-type benzodiazepine receptor: a protein of mitochondrial outer membranes utilizing porphyrins as endogenous ligands, FASEB J. 1 (1987) 282-288.
22. [22] A. Verma, S.H. Snyder. Peripheral type benzodiazepine receptors, Ann. Rev. Pharmacol. Toxicol. 29 (1989) 307-322.
23. [23] M. Mestre, T. Carriot, C. Belin, A. Uzan, C. Renault, M.C. Dubroeucq, C. Guérémy, G. Le Fur, Electrophysiological and pharmacological characterization of peripheral benzodiazepine receptors in a guinea pig heart preparation. Life Sciences 35 (1984) 953-962.
24. 3H]PK 11195, Brain Res. Bull. 13 (1984) 69-77.
25. 3H]PK 11195: anatomical and subcellular distribution, Brain Res. Bull, 18 (1987) 49-61.